英国癌症疫苗进展-认识和实现机会。

Cambridge prisms, Precision medicine Pub Date : 2025-01-20 eCollection Date: 2025-01-01 DOI:10.1017/pcm.2024.5
Charles Craddock, Philip Earwaker, Matthew Fittall, Elisa Fontana, Divya Ganesh, Marco Gerlinger, Qamar Ghafoor, Robert P Jones, Victoria Kunene, Lennard Lee, Rebecca Lee, Siow-Ming Lee, Mark Linch, Martin Little, Justin Liu, Hayley McKenzie, Russell Petty, David J Pinato, Thomas Powles, Andrew Protheroe, Tim Robinson, Paul J Ross, Kai Keen Shiu, James Spicer, Stefan Symeonides, Michael Tilby, Dale Vimalachandran, Jenny Y Wang, Andrew Wardley, Helen Winter
{"title":"英国癌症疫苗进展-认识和实现机会。","authors":"Charles Craddock, Philip Earwaker, Matthew Fittall, Elisa Fontana, Divya Ganesh, Marco Gerlinger, Qamar Ghafoor, Robert P Jones, Victoria Kunene, Lennard Lee, Rebecca Lee, Siow-Ming Lee, Mark Linch, Martin Little, Justin Liu, Hayley McKenzie, Russell Petty, David J Pinato, Thomas Powles, Andrew Protheroe, Tim Robinson, Paul J Ross, Kai Keen Shiu, James Spicer, Stefan Symeonides, Michael Tilby, Dale Vimalachandran, Jenny Y Wang, Andrew Wardley, Helen Winter","doi":"10.1017/pcm.2024.5","DOIUrl":null,"url":null,"abstract":"<p><p>Vaccines have revolutionised the field of medicine, eradicating and controlling many diseases. Recent pandemic vaccine successes have highlighted the accelerated pace of vaccine development and deployment. Leveraging this momentum, attention has shifted to cancer vaccines and personalised cancer vaccines, aimed at targeting individual tumour-specific abnormalities. The UK, now regarded for its vaccine capabilities, is an ideal nation for pioneering cancer vaccine trials. This article convened experts to share insights and approaches to navigate the challenges of cancer vaccine development with personalised or precision cancer vaccines, as well as fixed vaccines. Emphasising partnership and proactive strategies, this article outlines the ambition to harness national and local system capabilities in the UK; to work in collaboration with potential pharmaceutic partners; and to seize the opportunity to deliver the pace for rapid advances in cancer vaccine technology.</p>","PeriodicalId":72491,"journal":{"name":"Cambridge prisms, Precision medicine","volume":"3 ","pages":"e1"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811843/pdf/","citationCount":"0","resultStr":"{\"title\":\"UK cancer vaccine advance - Recognising and realising opportunities.\",\"authors\":\"Charles Craddock, Philip Earwaker, Matthew Fittall, Elisa Fontana, Divya Ganesh, Marco Gerlinger, Qamar Ghafoor, Robert P Jones, Victoria Kunene, Lennard Lee, Rebecca Lee, Siow-Ming Lee, Mark Linch, Martin Little, Justin Liu, Hayley McKenzie, Russell Petty, David J Pinato, Thomas Powles, Andrew Protheroe, Tim Robinson, Paul J Ross, Kai Keen Shiu, James Spicer, Stefan Symeonides, Michael Tilby, Dale Vimalachandran, Jenny Y Wang, Andrew Wardley, Helen Winter\",\"doi\":\"10.1017/pcm.2024.5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Vaccines have revolutionised the field of medicine, eradicating and controlling many diseases. Recent pandemic vaccine successes have highlighted the accelerated pace of vaccine development and deployment. Leveraging this momentum, attention has shifted to cancer vaccines and personalised cancer vaccines, aimed at targeting individual tumour-specific abnormalities. The UK, now regarded for its vaccine capabilities, is an ideal nation for pioneering cancer vaccine trials. This article convened experts to share insights and approaches to navigate the challenges of cancer vaccine development with personalised or precision cancer vaccines, as well as fixed vaccines. Emphasising partnership and proactive strategies, this article outlines the ambition to harness national and local system capabilities in the UK; to work in collaboration with potential pharmaceutic partners; and to seize the opportunity to deliver the pace for rapid advances in cancer vaccine technology.</p>\",\"PeriodicalId\":72491,\"journal\":{\"name\":\"Cambridge prisms, Precision medicine\",\"volume\":\"3 \",\"pages\":\"e1\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811843/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cambridge prisms, Precision medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1017/pcm.2024.5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cambridge prisms, Precision medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/pcm.2024.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

疫苗彻底改变了医学领域,根除和控制了许多疾病。最近在大流行性流感疫苗方面取得的成功突出表明,疫苗开发和部署的步伐正在加快。利用这一势头,注意力已转向癌症疫苗和个性化癌症疫苗,旨在针对个别肿瘤特异性异常。英国现在以其疫苗能力而闻名,是开展癌症疫苗试验的理想国家。这篇文章召集了专家,分享了个性化或精确癌症疫苗以及固定疫苗开发癌症疫苗挑战的见解和方法。本文强调伙伴关系和积极主动的战略,概述了在英国利用国家和地方系统能力的雄心;与潜在的医药合作伙伴合作;并抓住机会加快癌症疫苗技术的快速发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
UK cancer vaccine advance - Recognising and realising opportunities.

Vaccines have revolutionised the field of medicine, eradicating and controlling many diseases. Recent pandemic vaccine successes have highlighted the accelerated pace of vaccine development and deployment. Leveraging this momentum, attention has shifted to cancer vaccines and personalised cancer vaccines, aimed at targeting individual tumour-specific abnormalities. The UK, now regarded for its vaccine capabilities, is an ideal nation for pioneering cancer vaccine trials. This article convened experts to share insights and approaches to navigate the challenges of cancer vaccine development with personalised or precision cancer vaccines, as well as fixed vaccines. Emphasising partnership and proactive strategies, this article outlines the ambition to harness national and local system capabilities in the UK; to work in collaboration with potential pharmaceutic partners; and to seize the opportunity to deliver the pace for rapid advances in cancer vaccine technology.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信